It hasn't even been two weeks since
we last looked at what was on the dealmaking plate for Laurence Debroux, the CFO that's now also strategy chief at Sanofi-Aventis SA (NYSE:SNY), and the Paris firm has announced another two deals valued at over $1 billion.
The Deal Pipeline
shows Sanofi announced Wednesday that it is buying BiPar Sciences Inc. of Brisbane, Calif., for up to $500 million -- price depending on development and approval of the company's key anticancer drug. Pipeline notes the acquisition of BiPar represents a change of pace for Sanofi CEO Chris Viehbacher, who had previously concentrated his attentions on buying generic drugmakers in emerging countries. Before BiPar, Sanofi:
- acquired Brazilian generic drugmaker, Medley SA, for about $680 million,
- bought Mexican generic drug maker Laboratorios Kendrick and
- spent $1.9 billion to acquire Czech drugmaker Zentiva NV, making it the world's No. 11 maker of generic medicines.
A Wall Street Journal article shows that analysts say the latest deal casts doubts on speculation that Sanofi is poised to bid for the pharmaceutical business -- thought to be worth about $6.6 billion -- of Belgian group Solvay.
Debroux (pictured) certainly has a lot of integration work ahead of her, and she can count on one thing: More deals to come. -
Baz HiralalPress release: Sanofi acquires BiPar
Join Corporate Dealmaker's LinkedIn forum
Juergen Lasowski
And the winners are...
